TrialThe Lancet. Oncology2018

Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.

Owen A O'Connor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.